[
  {
    "date": "2023-12-30",
    "symbol": "GNFT",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "--12-31",
    "documentperiodenddate": "2023-12-31",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-38844",
    "entityregistrantname": "GENFIT S.A.",
    "entityincorporationstatecountrycode": "I0",
    "entityaddressaddressline1": "885, avenue Eugène Avinée",
    "entityaddresspostalzipcode": 59120,
    "entityaddresscityortown": "Loos",
    "entityaddresscountry": "FR",
    "contactpersonnelname": "Parc Eurasanté",
    "countryregion": 33,
    "cityareacode": "(0)3",
    "localphonenumber": "2016 4000",
    "contactpersonnelfaxnumber": "+33 (0)3 2016 4001",
    "security12btitle": "American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share",
    "tradingsymbol": "GNFT",
    "securityexchangename": "NASDAQ",
    "entitycommonstocksharesoutstanding": 49834983,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1757064,
    "documentfinstmterrorcorrectionflag": "false",
    "auditorname": "Ernst & Young et Autres",
    "auditorlocation": "Paris, France",
    "auditorfirmid": 1704,
    "cashandcashequivalents": 77789000,
    "tradeandothercurrentreceivables": 32707000,
    "othercurrentnonfinancialassets": 2615000,
    "inventories": 4000,
    "currentassets": 113115000,
    "intangibleassetsotherthangoodwill": 48761000,
    "propertyplantandequipment": 7872000,
    "othernoncurrentfinancialassets": 4125000,
    "noncurrentassets": 60758000,
    "assets": 173872000,
    "currentnotesanddebenturesissuedandcurrentportionofnoncurrentnotesanddebenturesissued": 415000,
    "othercurrentborrowingsandcurrentportionofothernoncurrentborrowings": 7510000,
    "tradeandothercurrentpayables": 18799000,
    "currentdeferredincomeotherthancurrentcontractliabilities": 11692000,
    "currentprovisions": 40000,
    "currenttaxliabilitiescurrent": 23000,
    "currentliabilities": 38480000,
    "noncurrentportionofnoncurrentnotesanddebenturesissued": 52206000,
    "noncurrentportionofothernoncurrentborrowings": 10047000,
    "noncurrentdeferredincomeotherthannoncurrentcontractliabilities": 3755000,
    "noncurrentprovisionsforemployeebenefits": 978000,
    "netdeferredtaxliabilities": 455000,
    "noncurrentliabilities": 67441000,
    "issuedcapital": 12459000,
    "sharepremium": 445261000,
    "retainedearningsexcludingprofitlossforreportingperiod": -361870000,
    "reserveofexchangedifferencesontranslation": 996000,
    "retainedearningsprofitlossforreportingperiod": -28894000,
    "equity": 67951000,
    "equityandliabilities": 173872000,
    "revenuefrominterest": 1709000,
    "netforeignexchangegain": 452000,
    "financeincomefromrenegotiationofdebt": 35600000,
    "otherfinanceincome": 1519000,
    "financeincome": 3680000,
    "interestexpense": 4553000,
    "interestexpensesforleases": 71000,
    "netforeignexchangeloss": 966000,
    "otherfinancecost": 23000,
    "financecosts": 5614000,
    "financeincomecost": -1934000,
    "percentageofdiscountofbonddebtateffectiveinterestrate": 0.088,
    "percentageofpaymentofcouponsrate": 0.035,
    "revenuefromrenderingofservices": 28565000,
    "otherrevenue": 9610000,
    "revenue": 38176000,
    "researchanddevelopmentexpense": 46503000,
    "generalandadministrativeexpense": 17741000,
    "salesandmarketingexpense": 876000,
    "expenseofrestructuringactivities": -505000,
    "otheroperatingincomeexpense": -141000,
    "profitlossfromoperatingactivities": -26580000,
    "profitlossbeforetax": -28514000,
    "incometaxexpensecontinuingoperations": 380000,
    "profitloss": -28894000,
    "basicearningslosspershare": -0.58,
    "dilutedearningslosspershare": -0.58,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": -51000,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": -785000,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossnetoftax": -836000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 2340000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 2340000,
    "comprehensiveincome": -27390000,
    "adjustmentsfordepreciationandamortisationexpense": 1654000,
    "adjustmentsforimpairmentandprovisionforlitigation": -392000,
    "adjustmentsforsharebasedpayments": 578000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": -81000,
    "adjustmentsforfinanceincomecost": -485000,
    "adjustmentsforincometaxexpense": 380000,
    "otheradjustmentsfornoncashitems": -878000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -27148000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -17418000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -10397000,
    "increasedecreaseinworkingcapital": 27815000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 465000,
    "cashflowsfromusedinoperatingactivities": -55429000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2074000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 414000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 172000,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 12000,
    "proceedsfromsalesormaturityoffinancialinstrumentsclassifiedasinvestingactivities": 4562000,
    "cashflowsfromusedininvestingactivities": 2234000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 89000,
    "repaymentsofloansandborrowings": 3619000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1075000,
    "interestpaidclassifiedasfinancingactivities": 2201000,
    "interestreceivedclassifiedasfinancingactivities": 1709000,
    "cashflowsfromusedinfinancingactivities": -5098000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -58292000,
    "effectofexchangeratechangesoncashandcashequivalents": 80000,
    "numberofsharesoutstanding": 49834983000,
    "othercomprehensiveincome": -836000,
    "increasedecreasethroughappropriationofretainedearnings": -23719000,
    "increasedecreasethroughsharebasedpaymenttransactions": 578000,
    "increasedecreasethroughtreasurysharetransactions": 8000,
    "increasedecreasethroughtransfersandotherchangesequity": 227000,
    "disclosureofcompanyinformationexplanatorytextblock": "THE COMPANY",
    "disclosureofmajoreventsintheperiodandeventsaftertheperiodexplanatorytextblock": "<span style=\"color:#000000;font-family:'Adelle Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:19.88pt\">MAJOR EVENTS IN THE PERIOD AND EVENTS AFTER THE PERIOD</span>",
    "disclosureofotherfinancialassetsexplanatorytextblock": "OTHER FINANCIAL ASSETS",
    "disclosureofbenefitpaymentsunderecompanysfrenchretiremententitytextblock": "The following assumed (undiscounted) benefit payments under the Company's French retirement indemnity are expected to be paid as follows:",
    "disclosureofdetailedinformationaboutsharecapitaltextblock": "Detailed breakdownShare capitalNumber of sharesAs of2022/12/312023/12/31Ordinary shares issued (€0.25 par value per share)49,834,98349,834,983Convertible preferred shares registered00Total shares issued49,834,98349,834,983Less treasury shares00Outstanding shares49,834,98349,834,983",
    "descriptionofaccountingpolicyforconsolidationexplanatorytextblock": "Consolidation",
    "descriptionofaccountingpolicyforotherincomeexplanatorytextblock": "Research tax credit",
    "disclosureofnoncurentassetsbygeographicalareatabletextblock": "Non-current assets break down by geographical area as follows: NON-CURRENT ASSETSAs of December 31, 2022As of December 31, 2023(thousands of euros)FranceSwitzerlandTotalFranceSwitzerlandTotalTOTAL12,92344,15857,08113,86946,88960,758",
    "disclosureofrevenuebreakdownbygeographicalareatabletextblock": "Revenue breakdown by geographical area Revenue by destinationYear ended(in € thousands)12/31/202112/31/202212/31/2023Revenue from France100 %100 %100 %Revenue from other countries— %— %— %TOTAL100 %100 %100 %",
    "disclosureofcashandcashequivalentsandshorttermdepositsclassifiedascashandcashequivalentsexplanatorytextblock": "These investments, summarized in the tables below, are short-term, highly liquid and subject to insignificant risk of changes in value.Cash and cash equivalentsAs of(in € thousands)2022/12/312023/12/31Short-term deposits119,090 67,530 Cash on hand and bank accounts16,910 10,258 TOTAL    136,001 77,789 Short-term depositsAs of(in € thousands)2022/12/312023/12/31TERM ACCOUNTS119,090 67,530 TOTAL    119,090 67,530",
    "disclosureofdetailedinformationabouttradeandotherreceivablesexplanatorytextblock": "Trade and other receivables consisted of the following:Trade and other receivables - TotalAs of(in € thousands)2022/12/312023/12/31Trade receivables, net3,188 18,526 Research tax credit11,299 12,200 Social security costs receivables1 — VAT receivables1,288 1,476 Grants receivables4 7 Other receivables126 498 TOTAL15,906 32,707 Of which : Current15,906 32,707 Of which : Non-current— —",
    "disclosureofdetailedinformationaboutbondstabletextblock": "As of 31/12/2022 :Number of bonds1,923,662Nominal amount of the loan56,940,395.20€Nominal unit value of the bonds29.60€Effective interest rate8.8%As of 31/12/2023 :Number of bonds1,923,662Nominal amount of the loan56,940,395.20€Nominal unit value of the bonds29.60€Effective interest rate8.8%",
    "disclosureofconvertibleloanstabletextblock": "Convertible loans - TotalAs of(in € thousands)2022/12/312023/12/31Convertible loans50,276 52,622 TOTAL50,27652,622Convertible loans - CurrentAs of(in € thousands)2022/12/312023/12/31Convertible loans415 415 TOTAL415415",
    "disclosureofchangeinprovisiontextblock": "Change in provisionsAs ofIncreaseDecreaseDecreaseAs of(in € thousands)2022/12/31(used)(unused)2023/12/31Provision for charges610(21)040TOTAL610(21)040",
    "disclosureofotherincomeexplanatorytextblock": "The breakdown of Other income is as follows:Other incomeYear ended(in € thousands)2021/12/312022/12/312023/12/31CIR tax credit5,282 6,017 5,807 Other operating income223 320 464 Government grants and subsidies5 34 3,340 TOTAL5,510 6,371 9,610",
    "additionalmilestonepayments": 65000000,
    "netassetsliabilities": 43939000,
    "totalacquiredliabilities": 2601000,
    "leaseliabilities": 282000,
    "totalacquiredassets": 46540000,
    "intangibleassetsandgoodwill": 43850000,
    "othercurrentassets": 197000,
    "closingforeignexchangeratechfeuro": 1.07991,
    "closingforeignexchangerateusdeuro": 0.90498,
    "impairmentloss": 9000,
    "rightofuseassets": 11067000,
    "buybackofdebtinstrumentsnumberofinstruments": 1923662,
    "borrowingsmaturity": "April 2017",
    "debtnominalunitvalue": 29.6,
    "numberofsharesissued": 49834983,
    "revenueremainingperformanceobligationvariableconsiderationamount": 2000000,
    "conversionexchangepremium": 5.5,
    "maximumdilutionofconvertibleinstrumentspercentage": 0.175,
    "notionalamount": 56940395.2,
    "revenuefromcontractswithcustomerspotentialmilestonepayments": 13300000,
    "proportionofownershipinterestinassociate": 0.0379,
    "debtsecurities": 57000000,
    "currentcontractliabilities": 40000000,
    "disclosureofmajoreventsintheperiodexplanatorytextblock": "Major events in the period",
    "provisionsforemployeebenefits": 978000,
    "averageforeignexchangerate": 1,
    "averageforeignexchangerateusdeuro": 0.92471,
    "averageforeignexchangeratechfeuro": 1.02936,
    "noncurrentassetsbygeographical": 13869000,
    "numberofsegment": 1,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P1Y",
    "researchtaxcreditcarryforwardperiod": "P3Y",
    "revenuebydestination": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P10Y",
    "operatingexpense": 15326000,
    "financialassets": 4095000,
    "cashcashequivalentsandfinancialassets": 60689000,
    "fluctuationincurrencyusdtoeur": 0.1,
    "financialliabilities": 70200000,
    "shorttermdepositsclassifiedascashequivalents": 67530000,
    "cash": 10258000,
    "additionsotherthanthroughbusinesscombinationsandamortisationintangibleassetsotherthangoodwill": 24000,
    "disposalsintangibleassetsotherthangoodwill": 45000,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 2746000,
    "increasedecreasethroughtransfersintangibleassetsotherthangoodwill": 18000,
    "increasedecreaseinintangibleassetsandgoodwill": 43900000,
    "descriptionofdiscountratesappliedtocashflowprojections": 0.12,
    "expectedsuccessrate": 0.151,
    "descriptionofgrowthrateusedtoextrapolatecashflowprojections": 0.02,
    "percentageamountbywhichvalueassignedtoweightedaveragecostofcapialinorderforunitsrecoverableamounttobeequaltocarryingamount": 0.054,
    "percentageamountbywhichvalueassignedtoexpectedrateofsuccessofprograminorderforrecoverableamounttobeequaltocarryingamount": 0.062,
    "additionsotherthanthroughbusinesscombinationsandaccumulateddepreciationandimpairmentpropertyplantandequipment": 427000,
    "disposalspropertyplantandequipment": 1378000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -3000,
    "revaluationincreasedecreasepropertyplantandequipment": 19000,
    "depreciationexpense": 4940000,
    "tradereceivables": 18526000,
    "valueaddedtaxreceivables": 1476000,
    "grantsreceivables": 7000,
    "otherreceivables": 498000,
    "tradeandotherreceivables": 32707000,
    "researchtaxcreditreceivable": 12200000,
    "investmentaccountedforusingequitymethod": 2348000,
    "otherinvestments": 471000,
    "financialinvestments": 4550000,
    "loansandreceivables": 472000,
    "depositsandguarantees": 303000,
    "liquiditycontractnet": 531000,
    "otherfinancialassets": 4125000,
    "loansandreceivablesvariations": 44000,
    "longtermdepositsandguaranteesvariations": 35000,
    "liquiditycontractvariations": 3000,
    "financialassetsvariations": 80000,
    "otherinvestmentsnumberofunitsofsubscription": 50,
    "otherinvestmentssubscriptionpaid": 175000,
    "otherinvestmentsremainingsubscription": 325000,
    "otherinvestmentspercentageofsubscriptionpaid": 0.35,
    "profitslossesondisposalofinvestmentsandchangesinvalueofinvestments": 12000,
    "numberofsharesrecordedasdeductionfromequity": 147812000,
    "amountbywhichtheassetwoulddecreaseiftheweightedaveragecostofcapital": 159000,
    "amountbywhichtheassetwoulddecreaseiftheestimatedoverallsuccessratedecreased": 212000,
    "conversionofconvertibleinstrumentsasapercentageofsharecapital": 0.212,
    "deferredtaxliabilityasset": 455000,
    "borrowingsinterestrate": 0.0087,
    "effectiveinterestrate": 0.088,
    "referenceshareprice": 22.77,
    "notesanddebenturesissued": 52622000,
    "otherborrowings": 11578000,
    "refundableandconditionaladvancesamountallocated": 3229000,
    "receiptsofrefundableandconditionaladvances": 3229000,
    "repaymentsofrefundableandconditionaladvances": -3229000,
    "refundableandconditionaladvancesgrantdate": "2008-12-23",
    "facilitysize": 800000,
    "installments": "60 monthly",
    "outstandingloans": 13000,
    "otherloansandborrowings": 57356000,
    "derivativefinancialliabilitiesundiscountedcashflows": 74913000,
    "financialassetsatfairvaluethroughprofitorloss": 471000,
    "financialassetsatfairvalue": 4550000,
    "financialliabilitiesatfairvalue": 51939000,
    "debtinstrumentsheld": 472000,
    "financialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 2348000,
    "tradeandotherpayablestotradesuppliers": 10448000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 4188000,
    "valueaddedtaxpayables": 3139000,
    "excisetaxpayables": 110000,
    "otherpayables": 914000,
    "tradeandotherpayables": 18799000,
    "currentpayablesonsocialsecurityandtaxesotherthanincometax": 4188000,
    "currentvalueaddedtaxpayables": 3139000,
    "currentexcisetaxpayables": 110000,
    "othercurrentpayables": 914000,
    "accruals": 4765000,
    "tradeandothercurrentpayablestotradesuppliers": 10448000,
    "currentcontractliabilitiesforperformanceobligationssatisfiedovertime": 120000000,
    "currentdeferredincomeincludingcurrentcontractliabilities": 11600000,
    "noncurrentdeferredincomeincludingnoncurrentcontractliabilities": 3800000,
    "deferredincomeotherthancontractliabilities": 15300000,
    "otherincome": 5807000,
    "partialrecognitionofdeferredrevenue": 8700000,
    "provisionforcharges": 21000,
    "postemploymentbenefitexpensedefinedcontributionplans": 948000,
    "populationdescription": "Permanent staff",
    "retirementage": 65,
    "termsofretirementdescription": "Initiated by the employee",
    "lifeexpectancydescription": "On the basis of the INSEE table (1)",
    "probabilityofcontinuedpresencedescription": "On the basis of the DARES table",
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.03,
    "actuarialassumptionofdiscountrates": 0.0359,
    "currentservicecostnetdefinedbenefitliabilityasset": 137000,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 25000,
    "pastservicecostnetdefinedbenefitliabilityasset": 51000,
    "increasedecreaseinnetdefinedbenefitliabilityassetresultingfromservicepaidtoemployees": -18000,
    "liabilityassetofdefinedbenefitplans": 978000,
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -28000,
    "percentageofreasonablypossibledecreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibledecreaseinactuarialassumption": 29000,
    "shareholderpaidinandregisteredperiodfordoublevotingrights": "P2Y",
    "additionalsharebasedinstrumentsissued": 525000,
    "revenuefromcontractswithcustomersnumberofperformanceobligations": 4,
    "salepriceclinicaltrialphase": 40000000,
    "reorganizationandrestructuringexpenses": -505000,
    "researchanddevelopmentexpensegeneralandadministrativeexpensemarketingandmarketaccessexpenseandotheroperatingincomeandexpense": -64756000,
    "averagenumberofemployees": 154,
    "sharebasedcompensationannualexpense": 578000,
    "wagesandsalaries": 14524000,
    "socialsecuritycontributions": 5296000,
    "adjustmentsforprovisions": 119000,
    "othershorttermemployeebenefits": 578000,
    "employeebenefitsexpense": 20517000,
    "numberofemployees": 78,
    "percentageofexercisableinstrumentsrelatingtocompanysrdprogramportfolio": 0.5,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofelafibranorinpbcandelativeclinical": 0.25,
    "percentageofexercisableinstrumentsrelatingtothedevelopmentofntzandtheaclffranchise": 0.15,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofthedevelopmentofthegns561program": 0.1,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 35070,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangementrelatingtocompanyrdprogramm": 5000,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangementrelatingtontzprogram": 1500,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangementrelatingtodevelopmentofthegns561program": 1000,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangementrelatingtodevelopmentofelafibranorinpbcandelativeclinical": 2500,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 2300,
    "exercisepriceshareoptionsgranted2019": 3.26,
    "estimatedfairvalueofshareaccordingtoifrs2": 4.05,
    "valuationmethodusedinsharebasedpaymentarrangements": "Monte Carlo",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.843,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0306,
    "conversionratio": "1:1",
    "numberofotherequityinstrumentssubscribedinsharebasedpaymentarrangement": 30900,
    "sharebasedcompensationacquisitionperiod": "From 03/10/2023to 03/13/2026",
    "priceofsharesatallocation": 4.05,
    "numberofotherequityinstrumentsawardedinsharebasedpaymentarrangement": 30900,
    "descriptionofexerciseperiodforsharebasedpaymentarrangement": "From 03/14/2023 to 03/13/2033",
    "grantdate": "2023-03-10",
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 35070,
    "numberofinstrumentsotherequityinstrumentsgranted": 35070,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 515000,
    "deferredtaxliabilities": 1183000,
    "deferredtaxassets": 842000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -586000,
    "averageeffectivetaxrate": 0.0133,
    "applicabletaxrate": 0.25,
    "taxexpenseincomeatapplicabletaxrate": -7129000,
    "taxeffectoftaxcredits": -1452000,
    "taxeffectofpermanentdifferences": 153000,
    "taxeffectofforeigntaxrates": 840000,
    "taxeffectoftaxlosses": 7832000,
    "taxeffectofadjustmentswithouttaxincidence": 145000,
    "taxeffectofnonrecognitionofdeferredtaxassetsrelatedtotemporarydifferences": -454000,
    "taxeffectofrecognitionofdeferredtaxassetsagainstdeferredtaxliabilities": 418000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 28000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": -523392000,
    "taxableprofitwithinoneyear": 1000000,
    "percentageofprofitexceedinglimitoffsettingtaxableprofit": 0.5,
    "taxlosscarriedforwardusedtooffsettaxableprofits": 33700000,
    "weightedaverageshares": 49700223000,
    "adjustedweightedaverageshares": 49700223000,
    "numberofsharesnonincludedinthecomputationofdilutedearningspershare": 35070000,
    "numberofcofoundersholdsharecapitalofrelatedparty": 4,
    "numberofemployeesholdsharecapitalofrelatedparty": 12,
    "keymanagementpersonnelcompensationattendancefees": 381000,
    "keymanagementpersonnelcompensationcontributioninkind": 23000,
    "keymanagementpersonnelcompensationsharebasedpayment": 72000,
    "keymanagementpersonnelcompensationemployercontributions": 396000,
    "keymanagementpersonnelcompensation": 1656000,
    "keymanagementpersonnelcompensationfixedcompensationfees": 614000,
    "keymanagementpersonnelcompensationvariablecompensationfees": 170000,
    "rentalpaymentobligationunderleaseagreement": 600000,
    "assetrecognisedforexpectedreimbursementcontingentliabilitiesinbusinesscombination": 193000000,
    "accruedpropertyplantandequipment": 42000
  },
  {
    "date": "2022-12-31",
    "symbol": "GNFT",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "--12-31",
    "documentperiodenddate": "2022-12-31",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-38844",
    "entityregistrantname": "GENFIT S.A.",
    "entityincorporationstatecountrycode": "I0",
    "entityaddressaddressline1": "885, avenue Eugène Avinée",
    "entityaddresspostalzipcode": 59120,
    "entityaddresscityortown": "Loos",
    "entityaddresscountry": "FR",
    "contactpersonnelname": "Parc Eurasanté",
    "countryregion": 33,
    "cityareacode": "(0)3",
    "localphonenumber": "2016 4000",
    "contactpersonnelfaxnumber": "+33 (0)3 2016 4001",
    "security12btitle": "American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share",
    "tradingsymbol": "GNFT",
    "securityexchangename": "NASDAQ",
    "entitycommonstocksharesoutstanding": 49834983,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1757064,
    "auditorname": "Ernst & Young et Autres",
    "auditorlocation": "Paris, France",
    "auditorfirmid": 1704,
    "cashandcashequivalents": 136001000,
    "tradeandothercurrentreceivables": 15906000,
    "othercurrentfinancialassets": 4550000,
    "othercurrentnonfinancialassets": 1998000,
    "inventories": 4000,
    "currentassets": 158459000,
    "intangibleassetsotherthangoodwill": 43957000,
    "propertyplantandequipment": 8210000,
    "othernoncurrentfinancialassets": 4914000,
    "noncurrentassets": 57081000,
    "assets": 215540000,
    "currentnotesanddebenturesissuedandcurrentportionofnoncurrentnotesanddebenturesissued": 415000,
    "othercurrentborrowingsandcurrentportionofothernoncurrentborrowings": 4665000,
    "tradeandothercurrentpayables": 14845000,
    "currentdeferredincomeotherthancurrentcontractliabilities": 14479000,
    "currentprovisions": 61000,
    "currenttaxliabilitiescurrent": 4906000,
    "currentliabilities": 39370000,
    "noncurrentportionofnoncurrentnotesanddebenturesissued": 49861000,
    "noncurrentportionofothernoncurrentborrowings": 20334000,
    "noncurrentpayables": 448000,
    "noncurrentdeferredincomeotherthannoncurrentcontractliabilities": 9706000,
    "noncurrentprovisionsforemployeebenefits": 782000,
    "netdeferredtaxliabilities": 510000,
    "noncurrentliabilities": 81641000,
    "issuedcapital": 12459000,
    "sharepremium": 444683000,
    "retainedearningsexcludingprofitlossforreportingperiod": -337550000,
    "reserveofexchangedifferencesontranslation": -1344000,
    "retainedearningsprofitlossforreportingperiod": -23719000,
    "equity": 94528000,
    "equityandliabilities": 215540000,
    "revenuefrominterest": 137000,
    "netforeignexchangegain": 7470000,
    "financeincomefromrenegotiationofdebt": 35600000,
    "otherfinanceincome": 605000,
    "financeincome": 8212000,
    "interestexpense": 4341000,
    "interestexpensesforleases": 69000,
    "netforeignexchangeloss": 340000,
    "otherfinancecost": 8000,
    "financecosts": 4758000,
    "financeincomecost": 3453000,
    "percentageofdiscountofbonddebtateffectiveinterestrate": 0.088,
    "percentageofpaymentofcouponsrate": 0.035,
    "revenuefromrenderingofservices": 20195000,
    "otherrevenue": 6371000,
    "revenue": 26566000,
    "researchanddevelopmentexpense": 35818000,
    "generalandadministrativeexpense": 16405000,
    "salesandmarketingexpense": 992000,
    "expenseofrestructuringactivities": -11000,
    "otheroperatingincomeexpense": -652000,
    "profitlossfromoperatingactivities": -27289000,
    "profitlossbeforetax": -23836000,
    "incometaxexpensecontinuingoperations": -116000,
    "profitloss": -23719000,
    "profitlossattributabletoownersofparent": -23719000,
    "basicearningslosspershare": -0.48,
    "dilutedearningslosspershare": -0.48,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 258000,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossnetoftax": 258000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -1366000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -1366000,
    "comprehensiveincome": -24827000,
    "comprehensiveincomeattributabletoownersofparent": -24827000,
    "adjustmentsfordepreciationandamortisationexpense": 1832000,
    "adjustmentsforimpairmentandprovisionforlitigation": -179000,
    "adjustmentsforsharebasedpayments": 245000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": -16000,
    "adjustmentsforfinanceincomecost": -2042000,
    "adjustmentsforincometaxexpense": -116000,
    "otheradjustmentsfornoncashitems": 2210000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -17702000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -8565000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -46226000,
    "increasedecreaseinworkingcapital": 54791000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 145000,
    "cashflowsfromusedinoperatingactivities": -72638000,
    "purchaseofinterestsinassociates": 41525000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": -251000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 20000,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 5012000,
    "cashflowsfromusedininvestingactivities": -46266000,
    "proceedsfromissuingshares": 5000,
    "repaymentsofloansandborrowings": 628000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1120000,
    "interestpaidclassifiedasfinancingactivities": 2180000,
    "interestreceivedclassifiedasfinancingactivities": 137000,
    "cashflowsfromusedinfinancingactivities": -3786000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -122690000,
    "effectofexchangeratechangesoncashandcashequivalents": -66000,
    "numberofsharesoutstanding": 49834983000,
    "othercomprehensiveincome": 258000,
    "increasedecreasethroughappropriationofretainedearnings": 67259000,
    "increasedecreaseinnumberofsharesoutstanding": 19494000,
    "increasedecreasethroughcapitalincrease": 5000,
    "increasedecreasethroughsharebasedpaymenttransactions": 245000,
    "increasedecreasethroughtreasurysharetransactions": 8000,
    "increasedecreasethroughtransfersandotherchangesequity": 5000,
    "lossesondisposalsofpropertyplantandequipment": 28000,
    "nameofacquiree": "Versantis AG",
    "dateofacquisition2013": "2022-09-29",
    "netassetsliabilities": 43939000,
    "totalacquiredliabilities": 2601000,
    "leaseliabilities": 282000,
    "totalacquiredassets": 46540000,
    "intangibleassetsandgoodwill": 43850000,
    "othercurrentassets": 197000,
    "closingforeignexchangerateusdeuro": 0.93756,
    "closingforeignexchangerate": 1,
    "impairmentloss": 97000,
    "rightofuseassets": 10665000,
    "buybackofdebtinstrumentsnumberofinstruments": 1923662,
    "borrowingsmaturity": "April 2016",
    "debtnominalunitvalue": 29.6,
    "numberofsharesissued": 49834983,
    "maximumdilutionofconvertibleinstrumentspercentage": 0.175,
    "notionalamount": 56940395.2,
    "revenuefromcontractswithcustomers": 1000000,
    "numberofsharesissuedduringperiod": 3985239,
    "proportionofownershipinterestinassociate": 0.08,
    "debtsecurities": 57000000,
    "revenuefromsalesofinventories": 3300000,
    "currentcontractliabilities": 40000000,
    "provisionsforemployeebenefits": 782000,
    "averageforeignexchangerate": 1,
    "averageforeignexchangerateusdeuro": 0.95105,
    "noncurrentassetsbygeographical": 12923000,
    "numberofsegment": 1,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P1Y",
    "researchtaxcreditcarryforwardperiod": "P3Y",
    "revenuebydestination": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P10Y",
    "operatingexpense": 14884000,
    "financialassets": 9456000,
    "cashcashequivalentsandfinancialassets": 110993000,
    "fluctuationincurrencyusdtoeur": 0.1,
    "financialliabilities": 75300000,
    "shorttermdepositsclassifiedascashequivalents": 119090000,
    "cash": 16910000,
    "additionsotherthanthroughbusinesscombinationsandamortisationintangibleassetsotherthangoodwill": 81000,
    "disposalsintangibleassetsotherthangoodwill": 398000,
    "increasedecreaseinintangibleassetsandgoodwill": 43900000,
    "additionsotherthanthroughbusinesscombinationsandaccumulateddepreciationandimpairmentpropertyplantandequipment": 610000,
    "disposalspropertyplantandequipment": 82000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 4000,
    "revaluationincreasedecreasepropertyplantandequipment": 2000,
    "depreciationexpense": 3839000,
    "tradereceivables": 3188000,
    "socialsecuritycostsreceivables": 1000,
    "valueaddedtaxreceivables": 1288000,
    "grantsreceivables": 4000,
    "otherreceivables": 126000,
    "tradeandotherreceivables": 15906000,
    "researchtaxcreditreceivable": 11299000,
    "increasedecreaseofresearchtaxcreditreceivable": 6017000,
    "investmentaccountedforusingequitymethod": 3133000,
    "otherinvestments": 483000,
    "financialinvestments": 4550000,
    "loansandreceivables": 428000,
    "depositsandguarantees": 335000,
    "liquiditycontractnet": 534000,
    "otherfinancialassets": 9464000,
    "loansandreceivablesvariations": 40000,
    "longtermdepositsandguaranteesvariations": 33000,
    "liquiditycontractvariations": 21000,
    "financialassetsvariations": 5107000,
    "otherinvestmentsnumberofunitsofsubscription": 50,
    "otherinvestmentssubscriptionpaid": 175000,
    "otherinvestmentsremainingsubscription": 325000,
    "otherinvestmentspercentageofsubscriptionpaid": 0.35,
    "profitslossesondisposalofinvestmentsandchangesinvalueofinvestments": 17000,
    "numberofsharesrecordedasdeductionfromequity": 138691000,
    "valuationassumptioncreditspread": 0.0874,
    "valuationassumptionvolatilityfirstlevel": 0.3,
    "valuationassumptionvolatilitysecondlevel": 0.35,
    "valuationassumptionnoriskrate": 0.0045,
    "numberofdebtinstrumentsissuedsubjecttoconversion": 10000,
    "conversionofconvertibleinstrumentsasapercentageofsharecapital": 0.2129,
    "deferredtaxliabilityasset": 510000,
    "numberofquarterlypaymentsamortizationandinterest": 8,
    "numberofquarterlypayments": 20,
    "borrowingsinterestrate": 0.0225,
    "borrowingsinterestratestateguaranteepercentage": 0.01,
    "effectiveinterestrate": 0.088,
    "interestpayable": 1993000,
    "numberofbiannualinstallments": 2,
    "borrowingsadjustmenttointerestratebasis": 0.0025,
    "referenceshareprice": 22.77,
    "notesanddebenturesissued": 50276000,
    "otherborrowings": 3229000,
    "refundableandconditionaladvancesamountallocated": 3229000,
    "receiptsofrefundableandconditionaladvances": 3229000,
    "refundableandconditionaladvancesnetbookvalue": 3229000,
    "refundableandconditionaladvancesgrantdate": "2008-12-23",
    "facilitysize": 4900000,
    "installments": "60 monthly",
    "outstandingloans": 54000,
    "refundableandconditionaladvances": 3229000,
    "otherloansandborrowings": 50276000,
    "derivativefinancialliabilitiesundiscountedcashflows": 75275000,
    "increaseinthedebts": 44000,
    "financialassetsatfairvaluethroughprofitorloss": 136001000,
    "financialassetsatfairvalue": 3133000,
    "financialliabilitiesatfairvalue": 3229000,
    "debtinstrumentsheld": 428000,
    "financialassetsmeasuredatfairvaluethroughothercomprehensiveincome": 3133000,
    "tradeandotherpayablestotradesuppliers": 8613000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 4838000,
    "valueaddedtaxpayables": 200000,
    "excisetaxpayables": 316000,
    "otherpayables": 1325000,
    "tradeandotherpayables": 15293000,
    "currentpayablesonsocialsecurityandtaxesotherthanincometax": 4838000,
    "currentvalueaddedtaxpayables": 200000,
    "currentexcisetaxpayables": 316000,
    "othercurrentpayables": 877000,
    "othernoncurrentpayables": 448000,
    "accruals": 3924000,
    "tradeandothercurrentpayablestotradesuppliers": 8613000,
    "currentcontractliabilitiesforperformanceobligationssatisfiedovertime": 120000000,
    "currentdeferredincomeincludingcurrentcontractliabilities": 14400000,
    "noncurrentdeferredincomeincludingnoncurrentcontractliabilities": 9700000,
    "deferredincomeotherthancontractliabilities": 24100000,
    "otherincome": 6017000,
    "partialrecognitionofdeferredrevenue": 15900000,
    "provisionforlitigation": 14000,
    "provisionforcharges": 4000,
    "postemploymentbenefitexpensedefinedcontributionplans": 876000,
    "populationdescription": "Permanent staff",
    "retirementage": 65,
    "termsofretirementdescription": "Initiated by the employee",
    "lifeexpectancydescription": "On the basis of the INSEE table (1)",
    "probabilityofcontinuedpresencedescription": "On the basis of the DARES table",
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.03,
    "actuarialassumptionofdiscountrates": 0.0325,
    "currentservicecostnetdefinedbenefitliabilityasset": 169000,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 8000,
    "pastservicecostnetdefinedbenefitliabilityasset": -258000,
    "liabilityassetofdefinedbenefitplans": 782000,
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -23000,
    "percentageofreasonablypossibledecreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibledecreaseinactuarialassumption": 24000,
    "benefitspaidorpayable": 37000,
    "shareholderpaidinandregisteredperiodfordoublevotingrights": "P2Y",
    "additionalsharebasedinstrumentsissued": 306435,
    "numberoffreesharesacquried": 19494,
    "revenuefromcontractswithcustomersnumberofperformanceobligations": 4,
    "salepriceclinicaltrialphase": 40000000,
    "expenserelatingtoresolutionofdispute": 1892000,
    "reorganizationandrestructuringexpenses": -11000,
    "researchanddevelopmentexpensegeneralandadministrativeexpensemarketingandmarketaccessexpenseandotheroperatingincomeandexpense": -53855000,
    "averagenumberofemployees": 133,
    "sharebasedcompensationannualexpense": 245000,
    "wagesandsalaries": 12188000,
    "socialsecuritycontributions": 4765000,
    "adjustmentsforprovisions": 169000,
    "othershorttermemployeebenefits": 245000,
    "employeebenefitsexpense": 17366000,
    "numberofemployees": 73,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 10782,
    "percentageofexercisableinstrumentsrelatingtocompanysrdprogramportfolio": 0.5,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofelafibranorinpbcandelativeclinical": 0.25,
    "percentageofexercisableinstrumentsrelatingtothedevelopmentofntzandtheaclffranchise": 0.15,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofthedevelopmentofthegns561program": 0.1,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 35070,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 18345,
    "exercisepriceshareoptionsgranted2019": 2.95,
    "estimatedfairvalueofshareaccordingtoifrs2": 4.08,
    "valuationmethodusedinsharebasedpaymentarrangements": "Monte Carlo",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.5,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0224,
    "conversionratio": "1:1",
    "numberofotherequityinstrumentssubscribedinsharebasedpaymentarrangement": 39200,
    "sharebasedcompensationacquisitionperiod": "From 14/10/2022 to 16/10/2025",
    "priceofsharesatallocation": 4.08,
    "numberofotherequityinstrumentsawardedinsharebasedpaymentarrangement": 39200,
    "descriptionofexerciseperiodforsharebasedpaymentarrangement": "From 3/12/2022 to 3/12/2032",
    "grantdate": "2022-10-14",
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 35070,
    "numberofinstrumentsotherequityinstrumentsgranted": 35070,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 7130000,
    "deferredtaxliabilities": 1770000,
    "deferredtaxassets": 1260000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -545000,
    "averageeffectivetaxrate": -0.0049,
    "applicabletaxrate": 0.25,
    "taxexpenseincomeatapplicabletaxrate": -5959000,
    "taxeffectoftaxcredits": -1504000,
    "taxeffectofpermanentdifferences": 31000,
    "taxeffectofforeigntaxrates": 67000,
    "taxeffectoftaxlosses": 7037000,
    "taxeffectofadjustmentswithouttaxincidence": 61000,
    "taxeffectofnonrecognitionofdeferredtaxassetsrelatedtotemporarydifferences": -331000,
    "taxeffectofrecognitionofdeferredtaxassetsagainstdeferredtaxliabilities": 453000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 29000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 477149000,
    "taxableprofitwithinoneyear": 1000000,
    "percentageofprofitexceedinglimitoffsettingtaxableprofit": 0.5,
    "taxlosscarriedforwardusedtooffsettaxableprofits": 33700000,
    "weightedaverageshares": 49673936000,
    "adjustedweightedaverageshares": 49673936000,
    "numberofsharesnonincludedinthecomputationofdilutedearningspershare": 35070000,
    "numberofcofoundersholdsharecapitalofrelatedparty": 4,
    "numberofemployeesholdsharecapitalofrelatedparty": 12,
    "keymanagementpersonnelcompensationattendancefees": 421000,
    "keymanagementpersonnelcompensationcontributioninkind": 21000,
    "keymanagementpersonnelcompensationsharebasedpayment": 74000,
    "keymanagementpersonnelcompensationemployercontributions": 410000,
    "keymanagementpersonnelcompensation": 1680000,
    "keymanagementpersonnelcompensationfixedcompensationfees": 585000,
    "keymanagementpersonnelcompensationvariablecompensationfees": 169000,
    "rentalpaymentobligationunderleaseagreement": 600000,
    "assetrecognisedforexpectedreimbursementcontingentliabilitiesinbusinesscombination": 193000000,
    "accruedpropertyplantandequipment": 142000
  },
  {
    "date": "2021-12-31",
    "symbol": "GNFT",
    "period": "FY",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "currentfiscalyearenddate": "--12-31",
    "documentperiodenddate": "2021-12-31",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-38844",
    "entityregistrantname": "GENFIT S.A.",
    "entityincorporationstatecountrycode": "I0",
    "entityaddressaddressline1": "885, avenue Eugène Avinée",
    "entityaddresspostalzipcode": 59120,
    "entityaddresscityortown": "Loos",
    "entityaddresscountry": "FR",
    "contactpersonnelname": "Parc Eurasanté",
    "countryregion": 33,
    "cityareacode": "(0)3",
    "localphonenumber": "2016 4000",
    "contactpersonnelfaxnumber": "+33 (0)3 2016 4001",
    "security12btitle": "American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share",
    "tradingsymbol": "GNFT",
    "securityexchangename": "NASDAQ",
    "entitycommonstocksharesoutstanding": 49815489,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entitycentralindexkey": 1757064,
    "auditorname": "Ernst & Young et Autres",
    "auditorlocation": "Paris, France",
    "auditorfirmid": 1704,
    "cashandcashequivalents": 258756000,
    "tradeandothercurrentreceivables": 7236000,
    "othercurrentnonfinancialassets": 2101000,
    "inventories": 4000,
    "currentassets": 268097000,
    "intangibleassetsotherthangoodwill": 174000,
    "propertyplantandequipment": 9015000,
    "noncurrentreceivables": 3000,
    "othernoncurrentfinancialassets": 4431000,
    "noncurrentassets": 13623000,
    "assets": 281720000,
    "currentnotesanddebenturesissuedandcurrentportionofnoncurrentnotesanddebenturesissued": 415000,
    "othercurrentborrowingsandcurrentportionofothernoncurrentborrowings": 1773000,
    "tradeandothercurrentpayables": 40988000,
    "currentdeferredincomeotherthancurrentcontractliabilities": 14298000,
    "currentprovisions": 313000,
    "currenttaxliabilitiescurrent": 5051000,
    "currentliabilities": 62837000,
    "noncurrentportionofnoncurrentnotesanddebenturesissued": 47682000,
    "noncurrentportionofothernoncurrentborrowings": 24365000,
    "noncurrentpayables": 450000,
    "noncurrentdeferredincomeotherthannoncurrentcontractliabilities": 25821000,
    "noncurrentprovisionsforemployeebenefits": 864000,
    "netdeferredtaxliabilities": 602000,
    "noncurrentliabilities": 99786000,
    "issuedcapital": 12454000,
    "sharepremium": 444438000,
    "retainedearningsexcludingprofitlossforreportingperiod": -405076000,
    "reserveofexchangedifferencesontranslation": 22000,
    "retainedearningsprofitlossforreportingperiod": 67259000,
    "equityattributabletoownersofparent": 119097000,
    "equity": 119097000,
    "equityandliabilities": 281720000,
    "revenuefromrenderingofservices": 80069000,
    "otherrevenue": 5510000,
    "revenue": 85579000,
    "researchanddevelopmentexpense": 35166000,
    "generalandadministrativeexpense": 16153000,
    "salesandmarketingexpense": 1539000,
    "expenseofrestructuringactivities": 142000,
    "otheroperatingincomeexpense": -763000,
    "profitlossfromoperatingactivities": 31816000,
    "financeincome": 44780000,
    "financecosts": 7122000,
    "financeincomecost": 37658000,
    "profitlossbeforetax": 69474000,
    "incometaxexpensecontinuingoperations": 2215000,
    "profitloss": 67259000,
    "profitlossattributabletoownersofparent": 67259000,
    "basicearningslosspershare": 1.51,
    "dilutedearningslosspershare": 1.23,
    "financeincomeconvertibledebt": 35578000,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 216000,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossnetoftax": 216000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 113000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 113000,
    "comprehensiveincome": 67589000,
    "comprehensiveincomeattributabletoownersofparent": 67589000,
    "adjustmentsfordepreciationandamortisationexpense": 2742000,
    "adjustmentsforimpairmentandprovisionforlitigation": -1996000,
    "adjustmentsforsharebasedpayments": 470000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": 420000,
    "adjustmentsforfinanceincomecost": -4663000,
    "adjustmentsforincometaxexpense": 2215000,
    "otheradjustmentsfornoncashitems": -35538000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": 40235000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 4344000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 55335000,
    "increasedecreaseinworkingcapital": -59680000,
    "cashflowsfromusedinoperatingactivities": 99915000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 537000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 309000,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 3148000,
    "cashflowsfromusedininvestingactivities": -3377000,
    "proceedsfromissuingshares": 27972000,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 15270000,
    "repaymentsofloansandborrowings": 48436000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 1887000,
    "interestpaidclassifiedasfinancingactivities": 2109000,
    "interestreceivedclassifiedasfinancingactivities": 274000,
    "cashflowsfromusedinfinancingactivities": -8916000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 87622000,
    "effectofexchangeratechangesoncashandcashequivalents": 105000,
    "numberofsharesoutstanding": 49815489000,
    "othercomprehensiveincome": 216000,
    "increasedecreasethroughappropriationofretainedearnings": -101221000,
    "increasedecreaseinnumberofsharesoutstanding": 10927110000,
    "increasedecreasethroughcapitalincrease": 2732000,
    "equitycomponentofbondsconvertibleorexchangeableintoneworexistingsharesnetofdeferredtaxes": 2311000,
    "increasedecreasethroughsharebasedpaymenttransactions": 470000,
    "increasedecreasethroughtreasurysharetransactions": -174000,
    "contractcostsrecognized": 3300000,
    "impairmentloss": 196000,
    "otherprovisions": 12000,
    "rightofuseassets": 62000,
    "borrowingsmaturity": "April 2016",
    "borrowings": 15300000,
    "reversalofprovisionsforcostofrestructuring": 366000,
    "unusedprovisionreversedotherprovisions": 352000,
    "provisionusedotherprovisions": 265000,
    "issuedcapitalordinaryshares": 12453872.25,
    "numberofsharesissuedandfullypaid": 49815489,
    "maximumdilutionofconvertibleinstrumentspercentage": 0.18,
    "feeandcommissionexpense": 2303000,
    "clinicaltrialrecruitmentperiod": "P18M",
    "numberofbankloans": 3,
    "borrowingsterm": "P1Y",
    "borrowingsoptionalrepaymentterm": "P6Y",
    "contractliabilities": 40000000,
    "revenuefromcontractswithcustomers": 80000000,
    "numberofsharesissuedduringperiod": 3985239,
    "revenuefromcontractswithcustomersvalueaddedtaxes": 24000000,
    "revenuefromcontractswithcustomerspotentialmilestonepayments": 360000000,
    "royaltyincomepercentofcollaborativesales": 0.2,
    "proportionofownershipinterestinassociate": 0.08,
    "provisionsforemployeebenefits": 864000,
    "closingforeignexchangerate": 0.88292,
    "averageforeignexchangerate": 0.8829,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P1Y",
    "numberofsegment": 1,
    "researchtaxcreditcarryforwardperiod": "P3Y",
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P10Y",
    "operatingexpense": 12566000,
    "financialassets": 4355000,
    "cashcashequivalentsandfinancialassets": 190964000,
    "fluctuationincurrencyusdtoeur": 0.1,
    "financialliabilities": 74200000,
    "debtsecurities": 57000000,
    "shorttermdepositsclassifiedascashequivalents": 69045000,
    "cash": 189711000,
    "additionsotherthanthroughbusinesscombinationsandamortisationintangibleassetsotherthangoodwill": 126000,
    "disposalsintangibleassetsotherthangoodwill": 255000,
    "increasedecreasethroughtransfersintangibleassetsotherthangoodwill": -17000,
    "additionsotherthanthroughbusinesscombinationsandaccumulateddepreciationandimpairmentpropertyplantandequipment": 71000,
    "disposalspropertyplantandequipment": 1912000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -5000,
    "revaluationincreasedecreasepropertyplantandequipment": 56000,
    "depreciationexpense": 2831000,
    "tradereceivables": 57000,
    "researchtaxcredit": 5282000,
    "socialsecuritycostsreceivables": 4000,
    "valueaddedtaxreceivables": 1038000,
    "grantsreceivables": 5000,
    "otherreceivables": 852000,
    "tradeandotherreceivables": 7239000,
    "currenttradereceivables": 57000,
    "currentresearchtaxcredit": 5282000,
    "currentsocialsecuritycostsreceivables": 4000,
    "currentvalueaddedtaxreceivables": 1038000,
    "currentgrantsreceivables": 3000,
    "othercurrentreceivables": 852000,
    "noncurrentgrantsreceivables": 3000,
    "creditnotesfromsuppliers": 752000,
    "investmentaccountedforusingequitymethod": 3133000,
    "loansandreceivables": 388000,
    "depositsandguarantees": 397000,
    "liquiditycontractnet": 513000,
    "otherfinancialassets": 4431000,
    "noncurrentloansandreceivables": 388000,
    "longtermdepositsandguarantees": 397000,
    "noncurrentliquiditycontractnet": 513000,
    "loansandreceivablesvariations": 36000,
    "longtermdepositsandguaranteesvariations": 107000,
    "liquiditycontractvariations": -175000,
    "financialassetsvariations": 3276000,
    "numberofsharesrecordedasdeductionfromequity": 137012,
    "valuationassumptioncreditspread": 0.0874,
    "valuationassumptionvolatilityfirstlevel": 0.3,
    "valuationassumptionvolatilitysecondlevel": 0.35,
    "valuationassumptionnoriskrate": 0.0045,
    "numberofdebtinstrumentsissuedsubjecttoconversion": 10000,
    "deferredtaxliabilityasset": 602000,
    "numberofquarterlypaymentsamortizationandinterest": 8,
    "numberofquarterlypayments": 20,
    "borrowingsinterestrate": 0.01,
    "borrowingsinterestratestateguaranteepercentage": 0.0028,
    "borrowingsrecognizedusingeffectiveinterestratelessthanayear": 125000,
    "debtinstrumentloandefermentoninterestperiod": "P1Y",
    "interestpayable": 1993000,
    "numberofbiannualinstallments": 2,
    "borrowingsadjustmenttointerestratebasis": 0.0025,
    "referenceshareprice": 22.77,
    "notesanddebenturesissued": 48097000,
    "otherborrowings": 3229000,
    "refundableandconditionaladvancesgrantdate": "2008-12-23",
    "refundableandconditionaladvancesamountallocated": 3229000,
    "receiptsofrefundableandconditionaladvances": 3229000,
    "refundableandconditionaladvancesnetbookvalue": 3229000,
    "facilitysize": 500000,
    "installments": "60 monthly",
    "outstandingloans": 115000,
    "refundableandconditionaladvances": 3229000,
    "otherloansandborrowings": 48097000,
    "derivativefinancialliabilitiesundiscountedcashflows": 74235000,
    "financialassetsatfairvaluethroughprofitorloss": 3133000,
    "reclassificationintoloansandreceivables": 388000,
    "financialassetsatfairvalue": 3133000,
    "financialliabilitiesatfairvalue": 3229000,
    "tradeandotherpayablestotradesuppliers": 12304000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 4087000,
    "valueaddedtaxpayables": 23725000,
    "excisetaxpayables": 744000,
    "otherpayables": 579000,
    "tradeandotherpayables": 41438000,
    "currentpayablesonsocialsecurityandtaxesotherthanincometax": 4087000,
    "currentvalueaddedtaxpayables": 23725000,
    "currentexcisetaxpayables": 744000,
    "othercurrentpayables": 128000,
    "othernoncurrentpayables": 450000,
    "accruals": 6201000,
    "accruedexpensesclinicaltrials": 900000,
    "accruedexpensesclinicaltrialsrequiringconversiontoeuros": 800000,
    "accruedexpensesclinicaltrialsbasedonexchangeratenet": 1200000,
    "currentcontractliabilitiesforperformanceobligationssatisfiedovertime": 120000000,
    "currentcontractliabilities": 40000000,
    "currentdeferredincomeincludingcurrentcontractliabilities": 14179000,
    "noncurrentdeferredincomeincludingnoncurrentcontractliabilities": 25821000,
    "postemploymentbenefitexpensedefinedcontributionplans": 774000,
    "liabilityassetofdefinedbenefitplans": 864000,
    "populationdescription": "Permanent staff",
    "termsofretirementdescription": "Initiated by the employee",
    "lifeexpectancydescription": "On the basis of the INSEE table",
    "probabilityofcontinuedpresencedescription": "On the basis of the DARES table",
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.03,
    "actuarialassumptionofdiscountrates": 0.0087,
    "currentservicecostnetdefinedbenefitliabilityasset": 154000,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 5000,
    "pastservicecostnetdefinedbenefitliabilityasset": -216000,
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -30000,
    "percentageofreasonablypossibledecreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibledecreaseinactuarialassumption": 31000,
    "shareholderpaidinandregisteredperiodfordoublevotingrights": "P2Y",
    "numberofshareswithdoublevotingrights": 2347639,
    "percentageofdoublevotingrights": 0.0471,
    "sharecapitalamount": 12453872.25,
    "sharesauthorized": 49815489,
    "parvaluepershare": 0.25,
    "additionalsharebasedinstrumentsissued": 323125,
    "revenuefromcontractswithcustomersnumberofperformanceobligations": 4,
    "salepriceclinicaltrialphase": 40000000,
    "otherincome": 5282000,
    "expenserelatingtoresolutionofdispute": 1892000,
    "gainslossesonexchangedifferencesontranslationbeforetax": 223000,
    "reorganizationandrestructuringexpenses": 142000,
    "researchanddevelopmentexpensegeneralandadministrativeexpensemarketingandmarketaccessexpenseandotheroperatingincomeandexpense": -53763000,
    "averagenumberofemployees": 122,
    "sharebasedcompensationannualexpense": 470000,
    "adjustmentsforprofitsharinggrantedtoemployees": 628000,
    "impairmentreorganizationofvacantpremises": 679000,
    "reversalofimpairmentlossrecognisedinprofitorloss": 441000,
    "wagesandsalaries": 10328000,
    "socialsecuritycontributions": 4775000,
    "adjustmentsforprovisions": 154000,
    "othershorttermemployeebenefits": 470000,
    "employeebenefitsexpense": 16354000,
    "numberofemployees": 55,
    "sharepriceperiodtodeterminevolatilityassumptions": "P2Y",
    "shareholdermeetingdate": "2019-11-27",
    "managementboardmeetingdate": "2021-10-18",
    "dateofdecisionanddelegationofboardofdirectorstoceo": "2021-02-26",
    "ceodecisiondate": "2021-03-30",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 29000,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 3400,
    "exercisepriceshareoptionsgranted2019": 3.26,
    "valuationmethodusedinsharebasedpaymentarrangements": "Monte Carlo",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.51,
    "descriptionofriskfreeinterestrateshareoptionsgranted": -0.59,
    "numberofotherequityinstrumentssubscribedinsharebasedpaymentarrangement": 32400,
    "sharebasedcompensationacquisitionperiod": "From 03/30/2021 to 03/31/2024",
    "priceofsharesatallocation": 4,
    "fairvalueofshareoptionssharebasedpaymentarrangement": 1.06,
    "numberofshareoptionssubscribedinsharebasedpaymentarrangement": 35000,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 7500,
    "numberofoutstandingshareoptions": 35000,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "From 10/20/2021 to 10/20/2024",
    "descriptionofexerciseperiodforsharebasedpaymentarrangement": "From 10/21/2024 to  10/21/2031",
    "percentageofexercisableinstrumentsrelatingtodevelopmentofelafibranorinpbcandelativeclinical": 0.5,
    "percentageofexercisableinstrumentsrelatingtothedevelopmentofntzandtheaclffranchise": 0.15,
    "percentageofexercisableinstrumentsrelatingtothenis4diagnostictechnology": 0.15,
    "percentageofexercisableinstrumentsrelatingtodevelopmentoftheproductpipelineofthecompany": 0.2,
    "percentageofexercisableinstrumentsrelatingtoni4diagnosticstechnology": 0.25,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofcompanypipeline": 0.25,
    "revenuefrominterest": 274000,
    "netforeignexchangegain": 8876000,
    "financeincomefromrenegotiationofdebt": 35578000,
    "otherfinanceincome": 52000,
    "interestexpense": 4846000,
    "interestexpensesforleases": 109000,
    "netforeignexchangeloss": 2163000,
    "otherfinancecost": 5000,
    "percentageofpaymentofcouponsrate": 0.035,
    "percentageofdiscountofbonddebtateffectiveinterestrate": 0.088,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 6713000,
    "deferredtaxliabilities": 2314000,
    "deferredtaxassets": 1712000,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -2721000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 2455000,
    "applicabletaxrate": 0.2737,
    "taxexpenseincomeatapplicabletaxrate": 19018000,
    "taxeffectoftaxcredits": -1512000,
    "taxeffectofpermanentdifferences": -833000,
    "taxeffectofforeigntaxrates": -7323000,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 5590000,
    "taxeffectofadjustmentswithouttaxincidence": 129000,
    "taxeffectofnonrecognitionofdeferredtaxassetsrelatedtotemporarydifferences": 24000,
    "taxeffectofrecognitionofdeferredtaxassetsagainstdeferredtaxliabilities": -430000,
    "taxeffectofrenegotiationofconvertibledebt": -1370000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 102000,
    "averageeffectivetaxrate": -0.0319,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 450679000,
    "taxableprofitwithinoneyear": 1000000,
    "percentageofprofitexceedinglimitoffsettingtaxableprofit": 0.5,
    "taxlosscarriedforwardusedtooffsettaxableprofits": 33700000,
    "deductibletemporarydifferencesforwhichnodeferredtaxassetisrecognised": 216000,
    "weightedaverageshares": 44739756000,
    "adjustedweightedaverageshares": 55613634000,
    "numberofcofoundersholdsharecapitalofrelatedparty": 4,
    "numberofemployeesholdsharecapitalofrelatedparty": 12,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 628000,
    "keymanagementpersonnelcompensationsharebasedpayment": 58000,
    "keymanagementpersonnelcompensation": 686000,
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the past twelve months ended",
    "ceocorporatecontractnoncompeteindemnitycompensationeligibilityperiod": "P12M",
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription1": "increased, where applicable, by the amount of the annual variable compensation due for the previous year. This compensation is intended to compensate the prohibition made to the Chief Executive Officer, for a period of 12 months following the termination of his functions, for whatever reason, to work in any way whatsoever with certain companies carrying out a directly competitive activity of the Company.",
    "ceogrossnegligenceseverancepaydescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the twelve past completed months",
    "ceogrossnegligenceseverancepaydescription1": "increased, where applicable, by the amount of annual variable compensation due for the previous year.",
    "maximumcommitmentamount": 523000,
    "ceogrossnegligenceseverancepayeligibilityperiod": "P12M",
    "insurancepremiumtobepaid": 2052000,
    "attendanceandotherremunerationpayable": 45863000,
    "attendanceandotherremunerationpayment": 39232000,
    "rentalpaymentobligationunderleaseagreement": 600000
  },
  {
    "date": "2020-12-31",
    "symbol": "GNFT",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "GENFIT S.A.",
    "entitycentralindexkey": 1757064,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 38888379,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "security12btitle": "American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share",
    "tradingsymbol": "GNFT",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-38844",
    "entityincorporationstatecountrycode": "I0",
    "entityaddressaddressline1": "Parc Eurasanté",
    "entityaddressaddressline2": "885, avenue Eugène Avinée",
    "entityaddresscityortown": "Loos",
    "entityaddresscountry": "FR",
    "entityaddresspostalzipcode": 59120,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Pascal Prigent",
    "countryregion": 33,
    "cityareacode": "3 20",
    "localphonenumber": "16 4000",
    "contactpersonnelfaxnumber": "33 (0)2 2016 4001",
    "cashandcashequivalents": 90637000,
    "tradeandothercurrentreceivables": 11919000,
    "othercurrentnonfinancialassets": 1765000,
    "inventories": 4000,
    "currentassets": 184717000,
    "intangibleassetsotherthangoodwill": -1531000,
    "propertyplantandequipment": 873000,
    "othernoncurrentfinancialassets": 1458000,
    "noncurrentassets": 13897000,
    "assets": 198614000,
    "shorttermconvertibleloans": 1313000,
    "currentborrowingsandcurrentportionofnoncurrentborrowings": 7000,
    "tradeandothercurrentpayables": 25564000,
    "deferredincomeclassifiedascurrent": 124000,
    "currentprovisions": 1031000,
    "currentliabilities": 31067000,
    "longtermconvertibleloans": 169470000,
    "longtermborrowings": 8046000,
    "noncurrentpayables": 451000,
    "noncurrentprovisionsforemployeebenefits": 1148000,
    "netdeferredtaxliabilities": 767000,
    "noncurrentliabilities": 183709000,
    "issuedcapital": 9722000,
    "sharepremium": 379057000,
    "retainedearnings": -303629000,
    "reserveofexchangedifferencesontranslation": -92000,
    "netincomelossnotincludedinretainedearning": -101221000,
    "equityattributabletoownersofparent": -16162000,
    "equity": -16162000,
    "equityandliabilities": 198614000,
    "revenuefromrenderingofservices": 765000,
    "otherrevenue": 6993000,
    "revenue": 7758000,
    "researchanddevelopmentexpense": 985000,
    "generalandadministrativeexpense": 495000,
    "salesandmarketingexpense": 90000,
    "expenseofrestructuringactivities": 5308000,
    "otheroperatingincomeexpense": -80000,
    "profitlossfromoperatingactivities": -82897000,
    "financeincome": 6544000,
    "financecosts": 25296000,
    "financeincomecost": -18752000,
    "profitlossbeforetax": -101649000,
    "incometaxexpensecontinuingoperations": -428000,
    "profitloss": -101221000,
    "profitlossattributabletoownersofparent": -101221000,
    "basicanddilutedearningslosspershare": -2.6,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 196000,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossnetoftax": 196000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -106000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -106000,
    "comprehensiveincome": -101131000,
    "comprehensiveincomeattributabletoownersofparent": -101131000,
    "adjustmentsfordepreciationandamortisationexpense": 3559000,
    "adjustmentsforimpairmentandprovisionforlitigation": 3015000,
    "adjustmentsforsharebasedpayments": 1236000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": 80000,
    "adjustmentsforfinanceincomecost": -10335000,
    "adjustmentsforincometaxexpense": -428000,
    "otheradjustmentsfornoncashitems": -1818000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -85242000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 318000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -11447000,
    "increasedecreaseinworkingcapital": 11129000,
    "cashflowsfromusedinoperatingactivities": -96371000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 900000,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 66000,
    "cashflowsfromusedininvestingactivities": -966000,
    "proceedsfromissuingshares": 7000,
    "repaymentsofloansandborrowings": -207000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 2150000,
    "interestpaidclassifiedasfinancingactivities": 7762000,
    "interestreceivedclassifiedasfinancingactivities": 1442000,
    "cashflowsfromusedinfinancingactivities": -8256000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -105593000,
    "effectofexchangeratechangesoncashandcashequivalents": -126000,
    "numberofsharesoutstanding": 38888379,
    "othercomprehensiveincome": 90000,
    "allocationofpriorperiodprofitloss": 65144000,
    "increasedecreasethroughcapitalincrease": -7000,
    "increasedecreaseinnumberofsharesoutstanding": 29762,
    "increasedecreasethroughsharebasedpaymenttransactions": 1236000,
    "increasedecreasethroughtreasurysharetransactions": -333000,
    "primaryandsecondaryendpointdescription": "For the primary efficacy endpoint, the response rate in the 717 patients enrolled on the study drug was 19.2% for patients who received elafibranor 120mg compared to 14.7% for patients in the placebo arm, which was not statistically significant (N.S.). On the fibrosis key secondary endpoint, 24.5% of patients who received elafibranor 120mg achieved fibrosis improvement of at least one stage compared to 22.4% in the placebo arm (N.S.).",
    "contractcostsrecognized": 9700000,
    "noncurrentprovisionclosingcost": 378000,
    "impairmentloss": 503000,
    "entitynumberofemployees": 130,
    "reorganizationcosts": 1850000,
    "renegotiationcostsestimated": 2400000,
    "renegotiationcostsrecognized": 745000,
    "borrowingsmaturity": "December 2014",
    "borrowings": 14908000,
    "closingforeignexchangerate": 0.81493,
    "averageforeignexchangerate": 0.87755,
    "nonrefundableupfrontpayment": 35000000,
    "potentialclinicalregulatoryandcommercialmilestonepaymentsmaximum": 193000000,
    "upfrontpaymentreceived": 35000000,
    "deferredupfrontpayment": 100000,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P8Y",
    "numberofsegment": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P6Y",
    "operatingexpense": 35025000,
    "financialassets": 172592000,
    "cashcashequivalentsandfinancialassets": 172486000,
    "financialliabilities": 206596000,
    "debtsecurities": 206596000,
    "shorttermdepositsclassifiedascashequivalents": 20147000,
    "cash": 4995000,
    "additionsotherthanthroughbusinesscombinationsandamortisationintangibleassetsotherthangoodwill": -102000,
    "disposalsintangibleassetsotherthangoodwill": 27000,
    "increasedecreasethroughtransfersintangibleassetsotherthangoodwill": 48000,
    "additionsotherthanthroughbusinesscombinationsandaccumulateddepreciationandimpairmentpropertyplantandequipment": -4676000,
    "disposalspropertyplantandequipment": 56000,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": 7000,
    "revaluationincreasedecreasepropertyplantandequipment": -80000,
    "reversalofimpairmentloss": 1182000,
    "rightsofuseandrelatedamortization": 2906000,
    "tradereceivables": 793000,
    "researchtaxcredit": 7911000,
    "socialsecuritycostsreceivables": 24000,
    "valueaddedtaxreceivables": 2766000,
    "grantsreceivables": 3000,
    "otherreceivables": 422000,
    "tradeandotherreceivables": 11919000,
    "currenttradereceivables": 793000,
    "currentresearchtaxcredit": 7911000,
    "currentsocialsecuritycostsreceivables": 24000,
    "currentvalueaddedtaxreceivables": 2766000,
    "currentgrantsreceivables": 3000,
    "othercurrentreceivables": 422000,
    "creditnotesfromsuppliers": 406000,
    "loansandreceivables": 352000,
    "depositsandguarantees": 418000,
    "liquiditycontractnet": 688000,
    "otherfinancialassets": 1458000,
    "noncurrentloansandreceivables": 352000,
    "longtermdepositsandguarantees": 418000,
    "numberofsharesrecordedasdeductionfromequity": 88929,
    "otherassets": 1765000,
    "debtredemptionpriortomaturityterms": "Redemption prior to maturity is at the option of the Company from November 6, 2020 if the arithmetic volume-weighted average price of the Company's share price and the then-prevailing conversion ratio (over a 20-day trading period) exceeds 150% of the nominal value of the OCEANEs.",
    "shorttermborrowings": 1312000,
    "interestpayable": 6300000,
    "creditderivativenominalamount": 180000000,
    "refundableandconditionaladvancesgrantdate": "2008-12-23",
    "refundableandconditionaladvancesamountallocated": 3229000,
    "receiptsofrefundableandconditionaladvances": 3229000,
    "refundableandconditionaladvancesnetbookvalue": 3229000,
    "facilitysize": 6715,
    "installments": "20 quarterly",
    "outstandingloans": 1540000,
    "refundableandconditionaladvances": 3229000,
    "otherloansandborrowings": 3184000,
    "derivativefinancialliabilitiesundiscountedcashflows": 6413000,
    "financialassetsatfairvaluethroughprofitorloss": 171029000,
    "reclassificationintoloansandreceivables": 1563000,
    "financialassetsatfairvalue": 1563000,
    "financialliabilitiesatfairvalue": 3229000,
    "tradeandotherpayablestotradesuppliers": 20337000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 4477000,
    "valueaddedtaxpayables": 314000,
    "excisetaxpayables": 319000,
    "otherpayables": 569000,
    "tradeandotherpayables": 26015000,
    "tradeandothercurrentpayablestotradesuppliers": 20337000,
    "currentpayablesonsocialsecurityandtaxesotherthanincometax": 4477000,
    "currentvalueaddedtaxpayables": 314000,
    "currentexcisetaxpayables": 319000,
    "othercurrentpayables": 118000,
    "othernoncurrentpayables": 451000,
    "accruals": 13809000,
    "accruedexpenses": 9600000,
    "accruedexpensesbasedonexchangeratenet": 10100000,
    "noncurrentprovisions": 51000,
    "researchtaxcreditdisputereversal": -1892000,
    "postemploymentbenefitexpensedefinedcontributionplans": 923000,
    "pastservicecostandgainslossesarisingfromsettlementsnetdefinedbenefitliabilityasset": -255000,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": -196000,
    "settlementofemployeesrights": 450000,
    "populationdescription": "Permanent staff",
    "actuarialassumptionofretirementage2019": "P65Y",
    "termsofretirementdescription": "Initiated by the employee",
    "lifeexpectancydescription": "On the basis of the INSEE table",
    "probabilityofcontinuedpresencedescription": "On the basis of the DARES table",
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.03,
    "actuarialassumptionofdiscountrates": 0.005,
    "liabilityassetofdefinedbenefitplans": 1148000,
    "currentservicecostnetdefinedbenefitliabilityasset": 181000,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 11000,
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -42000,
    "percentageofreasonablypossibledecreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibledecreaseinactuarialassumption": 45000,
    "numberofshareswithdoublevotingrights": 2332647,
    "percentageofdoublevotingrights": 0.06,
    "sharecapitalamount": 9714654.25,
    "sharesauthorized": 38888379,
    "sharessubscribed": 38888379,
    "paidupshares": 38888379,
    "parvaluepershare": 0.25,
    "additionalsharebasedinstrumentsissued": 407900,
    "numberofsharesvested": 29762,
    "otherincome": 6993000,
    "gainslossesonexchangedifferencesontranslationbeforetax": 951000,
    "reorganizationandrestructuringexpenses": 3175000,
    "researchanddevelopmentexpensegeneralandadministrativeexpensemarketingandmarketaccessexpenseandotheroperatingincomeandexpense": -80000,
    "depreciationamortisationandimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 363000,
    "provisiontoresearchtaxcreditlitigation": 1800000,
    "reversalofprovisionoftaxcontrolontaxcredit": 1800000,
    "numberofemployees": 78,
    "accrualsandprovisionsrecognizedwithinscopeofpse": 1850000,
    "restructuringprovision": 378000,
    "terminationbenefitsexpense": 1327000,
    "wagesandsalaries": 13570000,
    "socialsecuritycontributions": 5047000,
    "adjustmentsforprovisions": -74000,
    "othershorttermemployeebenefits": 1236000,
    "employeebenefitsexpense": 19779000,
    "averagenumberofemployees": 193,
    "averageageofemployees": "P38Y8M",
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 1233,
    "expensefromsharebasedpaymenttransactionsrecognizedduetonewaccountingstandardadopted": 1236000,
    "sharepriceperiodtodeterminevolatilityassumptions": "P3Y",
    "sharebasedcompensationannualexpense": 1236000,
    "shareholdermeetingdate": "2019-11-27",
    "managementboardmeetingdate": "2014-09-16",
    "dateofdecisionanddelegationofboardofdirectorstoceo": "2020-12-11",
    "ceodecisiondate": "2020-12-11",
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 61484,
    "issuepricepersharewarrants": 23.5,
    "exercisepriceshareoptionsgranted2019": 4.52,
    "valuationmethodusedinsharebasedpaymentarrangements": "Black-Scholes",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.49,
    "descriptionofriskfreeinterestrateshareoptionsgranted": -0.007,
    "descriptionofexpectedlifesharewarrantsgranted": "P4Y",
    "numberofotherequityinstrumentssubscribedinsharebasedpaymentarrangement": 62717,
    "sharewarrantssubscriptionperiod": "voided on 09/2018 - 05/2019 and 07/2019",
    "estimatedfairvalueofsharewarrant": 11.29,
    "priceofsharesatallocation": 3.99,
    "numberofshareoptionssubscribedinsharebasedpaymentarrangement": 56250,
    "numberofoutstandingshareoptions": 48750,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "From 12/31/2020 to 12/31/2023",
    "descriptionofexerciseperiodforsharebasedpaymentarrangement": "From 01/01/2024 to 12/31/2027",
    "fairvalueofshareoptionssharebasedpaymentarrangement": 1.12,
    "evaluationdateforperformanceconditions": "31/12/2023",
    "descriptionofnatureofconditions": "25% of the 2020 instruments will be exercisable if at least if at least one of the two following conditions relating to the development of the Company’s pipeline is fulfilled:(i) a new clinical trial for a new indication with elafibranor or NTZ in ongoing or complete;(ii) the Company has developed or acquired the rights of a new molecule.",
    "percentageofexercisableinstrumentsrelatingtodevelopmentofelafibranorinpbcandelativeclinical": 0.5,
    "percentageofexercisableinstrumentsrelatingtoni4diagnosticstechnology": 0.25,
    "percentageofexercisableinstrumentsrelatingtodevelopmentofcompanypipeline": 0.25,
    "revenuefrominterest": 1442000,
    "netforeignexchangegain": 4983000,
    "otherfinanceincome": 119000,
    "interestexpense": 11643000,
    "interestexpensesforleases": 134000,
    "netforeignexchangeloss": 13508000,
    "otherfinancecost": 11000,
    "percentageofpaymentofcouponsrate": 0.035,
    "percentageofdiscountofbonddebtateffectiveinterestrate": 0.072,
    "foreigncurrencytransactionlossbeforetax": 8525000,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 483356000,
    "taxableprofitwithinoneyear": 1000000,
    "percentageofprofitexceedinglimitoffsettingtaxableprofit": 0.5,
    "deferredtaxliabilities": 2050000,
    "deferredtaxassets": 1282000,
    "weightedaverageshares": 38858617,
    "basicearningslosspersharefromcontinuingoperations": -2.6,
    "numberofcofoundersholdsharecapitalofrelatedparty": 4,
    "numberofemployeesholdsharecapitalofrelatedparty": 12,
    "percentageofsharecapitalheldbyrelatedparty": 0.0486,
    "endowmentfundbalance": 17000,
    "relatedpartytransactioncost": 255000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 534000,
    "keymanagementpersonnelcompensationsharebasedpayment": 41000,
    "keymanagementpersonnelcompensation": 575000,
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the past twelve months ended",
    "ceocorporatecontractnoncompeteindemnitycompensationeligibilityperiod": "P12M",
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription1": "increased, where applicable, by the amount of the annual variable compensation due for the previous year. This compensation is intended to compensate the prohibition made to the Chief Executive Officer, for a period of 12 months following the termination of his functions, for whatever reason, to work in any way whatsoever with certain companies carrying out a directly competitive activity of the Company.",
    "ceogrossnegligenceseverancepaydescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the twelve past completed months",
    "ceogrossnegligenceseverancepayeligibilityperiod": "P12M",
    "maximumcommitmentamount": 415000,
    "insurancepremiumtobepaid": 1316000,
    "attendanceandotherremunerationpayable": 650276000,
    "attendanceandotherremunerationpayment": 603408000,
    "rentalpaymentobligationunderleaseagreement": 600000
  },
  {
    "date": "2019-12-31",
    "symbol": "GNFT",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "GENFIT S.A.",
    "entitycentralindexkey": 1757064,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 38858617,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "security12btitle": "American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share",
    "tradingsymbol": "GNFT",
    "securityexchangename": "NASDAQ",
    "entityfilenumber": "001-38844",
    "entityincorporationstatecountrycode": "I0",
    "entityaddressaddressline1": "Parc Eurasanté",
    "entityaddressaddressline2": "885, avenue Eugène Avinée",
    "entityaddresscityortown": "Loos",
    "entityaddresscountry": "FR",
    "entityaddresspostalzipcode": 59120,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelname": "Pascal Prigent",
    "countryregion": 33,
    "cityareacode": "3 20",
    "localphonenumber": "16 4000",
    "contactpersonnelfaxnumber": "33 (0)2 2016 4001",
    "cashandcashequivalents": 136884000,
    "tradeandothercurrentreceivables": 12033000,
    "othercurrentnonfinancialassets": 1968000,
    "inventories": 4000,
    "currentassets": 290753000,
    "intangibleassetsotherthangoodwill": -1910000,
    "propertyplantandequipment": 1413000,
    "othernoncurrentfinancialassets": 1727000,
    "noncurrentassets": 19099000,
    "assets": 309853000,
    "shorttermconvertibleloans": 1312000,
    "currentborrowingsandcurrentportionofnoncurrentborrowings": 7000,
    "tradeandothercurrentpayables": 36917000,
    "deferredincomeclassifiedascurrent": 139000,
    "currentprovisions": 2061000,
    "currentliabilities": 43657000,
    "longtermconvertibleloans": 164142000,
    "longtermborrowings": 10169000,
    "noncurrentpayables": 450000,
    "noncurrentprovisionsforemployeebenefits": 1408000,
    "netdeferredtaxliabilities": 1193000,
    "noncurrentliabilities": 182132000,
    "issuedcapital": 9715000,
    "sharepremium": 377821000,
    "retainedearnings": -238340000,
    "reserveofexchangedifferencesontranslation": 14000,
    "netincomelossnotincludedinretainedearning": -65144000,
    "equityattributabletoownersofparent": 84065000,
    "equity": 84065000,
    "equityandliabilities": 309853000,
    "revenuefromrenderingofservices": 30839000,
    "otherrevenue": 10122000,
    "revenue": 40961000,
    "researchanddevelopmentexpense": 4716000,
    "generalandadministrativeexpense": 458000,
    "salesandmarketingexpense": 76000,
    "otheroperatingincomeexpense": 19000,
    "profitlossfromoperatingactivities": -57832000,
    "financeincome": 5221000,
    "financecosts": 13110000,
    "financeincomecost": -7889000,
    "profitlossbeforetax": -65721000,
    "incometaxexpensecontinuingoperations": -576000,
    "profitloss": -65144000,
    "profitlossattributabletoownersofparent": -65144000,
    "basicanddilutedearningslosspershare": -1.76,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": -168000,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossnetoftax": -168000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 8000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 8000,
    "comprehensiveincome": -65304000,
    "comprehensiveincomeattributabletoownersofparent": -65304000,
    "adjustmentsfordepreciationandamortisationexpense": 3263000,
    "adjustmentsforimpairmentandprovisionforlitigation": 357000,
    "adjustmentsforsharebasedpayments": 1657000,
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": -19000,
    "adjustmentsforfinanceincomecost": -11437000,
    "adjustmentsforincometaxexpense": -576000,
    "otheradjustmentsfornoncashitems": 1702000,
    "cashflowsfromusedinoperationsbeforechangesinworkingcapital": -47324000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -1640000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 1284000,
    "increasedecreaseinworkingcapital": 356000,
    "cashflowsfromusedinoperatingactivities": -47680000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2030000,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 2517000,
    "purchaseoffinancialinstrumentsclassifiedasinvestingactivities": 160000,
    "cashflowsfromusedininvestingactivities": 327000,
    "proceedsfromissuingshares": 126486000,
    "proceedsfromsubscriptionorexerciseofsharewarrants": 43000,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 1884000,
    "interestpaidclassifiedasfinancingactivities": 7785000,
    "cashflowsfromusedinfinancingactivities": 116860000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 69508000,
    "numberofsharesoutstanding": 38858617,
    "othercomprehensiveincome": -160000,
    "allocationofpriorperiodprofitloss": 79521000,
    "increasedecreasethroughcapitalincrease": 126479000,
    "increasedecreaseinnumberofsharesoutstanding": 7674696,
    "increasedecreasethroughsharebasedpaymenttransactions": 1657000,
    "increasedecreasethroughtreasurysharetransactions": 252000,
    "increasedecreasethroughtransfersandotherchangesequity": 43000,
    "numberofsharesissued": 7647500,
    "proceedsfromissueofordinaryshares": 137600000,
    "closingforeignexchangerate": 0.89015,
    "shareissuerelatedcost": 12300000,
    "upfrontpaymentreceived": 35000000,
    "potentialclinicalregulatoryandcommercialmilestonepaymentsmaximum": 193000000,
    "lesseeoperatingleasetermofcontract1": "P9Y",
    "constructioncostsmaximumamountthatwillbereimbursedbylessor": 2500000,
    "averageforeignexchangerate": 0.89341,
    "nonrefundableupfrontpayment": 35000000,
    "revenuethatwasincludedincontractliabilitybalanceatbeginningofperiod": 34900000,
    "deferredupfrontpayment": 100000,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P8Y",
    "weightedaveragelesseesincrementalborrowingrateappliedtoleaseliabilitiesrecognisedatdateofinitialapplicationofifrs16": 0.0126,
    "numberofsegment": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P6Y",
    "operatingexpense": 32657000,
    "financialassets": 277658000,
    "cashcashequivalentsandfinancialassets": 278474000,
    "financialliabilities": 216898000,
    "shorttermdepositsclassifiedascashequivalents": 45033000,
    "cash": 13601000,
    "additionsotherthanthroughbusinesscombinationsandamortisationintangibleassetsotherthangoodwill": 125000,
    "disposalsintangibleassetsotherthangoodwill": -29000,
    "increasedecreasethroughtransfersintangibleassetsotherthangoodwill": -378000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 10429000,
    "disposalspropertyplantandequipment": 1741000,
    "revaluationincreasedecreasepropertyplantandequipment": 1496000,
    "interestcostscapitalised": 2500000,
    "borrowingcostsincurred": 2500000,
    "additionalcostincurred": 1300000,
    "constructioncostincurred": 2500000,
    "leaseholdimprovements": 300000,
    "amortizedleaseholdimprovements": "P10Y",
    "rightofuseassetsanddepreciation": 4346000,
    "tradereceivables": 207000,
    "researchtaxcredit": 8125000,
    "socialsecuritycostsreceivables": 5000,
    "valueaddedtaxreceivables": 1814000,
    "grantsreceivables": 3000,
    "otherreceivables": 420000,
    "tradeandotherreceivables": 12033000,
    "currenttradereceivables": 207000,
    "currentresearchtaxcredit": 9585000,
    "currentsocialsecuritycostsreceivables": 5000,
    "currentvalueaddedtaxreceivables": 1814000,
    "currentgrantsreceivables": -3000,
    "othercurrentreceivables": 420000,
    "partialpaymentofresearchtaxcreditassessmentduetoongoingtaxaudit": 333000,
    "gainslossesonlitigationsettlements": 432000,
    "provisionfortaxliability": 1892000,
    "creditnotesfromsuppliers": 408000,
    "loansandreceivables": 307000,
    "depositsandguarantees": 396000,
    "liquiditycontractnet": 1023000,
    "otherfinancialassets": 1727000,
    "noncurrentloansandreceivables": 307000,
    "longtermdepositsandguarantees": 396000,
    "numberofsharesrecordedasdeductionfromequity": 18132,
    "otherassets": 1968000,
    "debtsecurities": 216898000,
    "borrowingsinterestrate": 0.035,
    "borrowingsmaturity": "December 2014",
    "debtredemptionpriortomaturityterms": "Redemption prior to maturity is at the option of the Company from November 6, 2020 if the arithmetic volume-weighted average price of the Company's share price and the then-prevailing conversion ratio (over a 20-day trading period) exceeds 150% of the nominal value of the OCEANEs.",
    "borrowings": 18165000,
    "shorttermborrowings": 1312000,
    "dilutiveeffectofconvertibleinstrumentsexpressedaspercentageofsharecapital": 0.156,
    "percentageofnoninterestbearingadvancesrepayabletonominalamount": 1,
    "additionalremunerationdescription": "The loan agreement has a provision applicable during the reimbursement period which provides for additional remuneration to BPI France depending on whether the Company had industrial income. This additional remuneration amounts to 0.2294% of sales.",
    "loanrepaymentmaturity": "June 2017",
    "interestpayable": 6300000,
    "creditderivativenominalamount": 180000000,
    "refundableandconditionaladvancesgrantdate": "2008-12-23",
    "refundableandconditionaladvancesamountallocated": 3229000,
    "receiptsofrefundableandconditionaladvances": 3229000,
    "refundableandconditionaladvancesnetbookvalue": 3229000,
    "facilitysize": 500,
    "installments": "20 quarterly",
    "outstandingloans": 2645000,
    "refundableandconditionaladvances": 3229000,
    "otherloansandborrowings": 4223000,
    "derivativefinancialliabilitiesundiscountedcashflows": 7452000,
    "financialassetsatfairvaluethroughprofitorloss": 276748000,
    "reclassificationintoloansandreceivables": 911000,
    "financialassetsatfairvalue": 911000,
    "financialliabilitiesatfairvalue": 3229000,
    "tradeandotherpayablestotradesuppliers": 32753000,
    "payablesonsocialsecurityandtaxesotherthanincometax": 3581000,
    "employeeprofitsharing": 17000,
    "valueaddedtaxpayables": 2000,
    "excisetaxpayables": 487000,
    "otherpayables": 527000,
    "tradeandotherpayables": 37368000,
    "tradeandothercurrentpayablestotradesuppliers": 32753000,
    "currentpayablesonsocialsecurityandtaxesotherthanincometax": 3581000,
    "currentemployeeprofitsharing": 17000,
    "currentvalueaddedtaxpayables": 2000,
    "currentexcisetaxpayables": 487000,
    "othercurrentpayables": 76000,
    "othernoncurrentpayables": 450000,
    "postemploymentbenefitexpensedefinedcontributionplans": 927000,
    "populationdescription": "Permanent staff",
    "actuarialassumptionofretirementage2019": "P65Y",
    "termsofretirementdescription": "Initiated by the employee",
    "lifeexpectancydescription": "On the basis of the INSEE table",
    "probabilityofcontinuedpresencedescription": "On the basis of the DARES table",
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.03,
    "actuarialassumptionofdiscountrates": 0.0075,
    "liabilityassetofdefinedbenefitplans": 1408000,
    "currentservicecostnetdefinedbenefitliabilityasset": 138000,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 17000,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": 168000,
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -51000,
    "percentageofreasonablypossibledecreaseinactuarialassumption": 0.0025,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibledecreaseinactuarialassumption": 53000,
    "numberofshareswithdoublevotingrights": 2311439,
    "percentageofdoublevotingrights": 0.0595,
    "numberofsharesvested": 19400,
    "otherincome": 10122000,
    "gainslossesonexchangedifferencesontranslationbeforetax": 1985000,
    "researchanddevelopmentexpensegeneralandadministrativeexpensemarketingandmarketaccessexpenseandotheroperatingincomeandexpense": 19000,
    "decreaseinamountrecognizedforinvoicesnotreceived": 6994000,
    "wagesandsalaries": 14018000,
    "socialsecuritycontributions": 5171000,
    "adjustmentsforprovisions": 138000,
    "othershorttermemployeebenefits": 1657000,
    "employeebenefitsexpense": 20984000,
    "averagenumberofemployees": 175,
    "averageageofemployees": "P37Y1M",
    "numberofemployees": 116,
    "expensefromsharebasedpaymenttransactionsrecognizedduetonewaccountingstandardadopted": 1645000,
    "numberofyearsofsuccessiveplan": "P4Y",
    "existingturnoverrateassumption": 0.15,
    "sharepriceperiodtodeterminevolatilityassumptions": "P3Y",
    "sharebasedcompensationannualexpense": 1645000,
    "sharebasedcompensationannualexpensecalculated": 7787000,
    "sharebasedcompensationannualexpenseremaining": 2004000,
    "shareholdermeetingdate": "2019-11-27",
    "managementboardmeetingdate": "2014-09-16",
    "dateofdecisionanddelegationofboardofdirectorstoceo": "2019-11-27",
    "ceodecisiondate": "2019-11-27",
    "beneficiariesinsharebasedpaymentarrangements": "Consultants",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 16854,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 702,
    "numberofsharewarrantsremaininginsharebasedpaymentarrangement": 35070,
    "issuepricepersharewarrants": 23.5,
    "exercisepriceshareoptionsgranted2019": 14.31,
    "estimatedfairvalueofshareaccordingtoifrs2": 0.75,
    "sharewarrantsexerciseperiod": "voided on  09.2018 - 05.2019 and 07.2019",
    "valuationmethodusedinsharebasedpaymentarrangements": "Monte Carlo",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.4,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.004,
    "descriptionofexpectedlifesharewarrantsgranted": "P4Y",
    "numberofotherequityinstrumentssubscribedinsharebasedpaymentarrangement": 17556,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 1233,
    "estimatedfairvalueofsharewarrant": 11.29,
    "dateofexecutiveboardmeeting": "2019-07-18",
    "sharebasedcompensationacquisitionperiod": "From 07/18/2019 to 09/16/2022",
    "priceofsharesatallocation": 14.5,
    "numberofshareoptionssubscribedinsharebasedpaymentarrangement": 13350,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 1780,
    "numberofoutstandingshareoptions": 13350,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "From 11/27/2019 to 01/16/2023",
    "descriptionofexerciseperiodforsharebasedpaymentarrangement": "From 01/17/2023 to 01/17/2030",
    "fairvalueofshareoptionssharebasedpaymentarrangement": 3.23,
    "evaluationdateforperformanceconditions": "07/31/2022",
    "descriptionofnatureofinternalconditions": "The free shares will definitively vest upon the same internal performance conditions as the  SO 2019, SO US 2019 and AGA D 2019 plans",
    "percentageofexercisableordefinitivelyallocatedinstrumentsregardlessofstockmarketpricevariation": 0.6667,
    "percentageofexercisableordefinitivelyallocatedinstrumentsproportiontostockmarketpriceevolution": 0.3333,
    "revenuefrominterest": 2626000,
    "netforeignexchangegain": 2272000,
    "otherfinanceincome": 324000,
    "interestexpense": 11289000,
    "interestexpensesforleases": 148000,
    "netforeignexchangeloss": 1657000,
    "otherfinancecost": 17000,
    "discountingofborrowingseffectiveinterestrate": 0.072,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 384471000,
    "taxableprofitwithinoneyear": 1000000,
    "percentageofprofitexceedinglimitoffsettingtaxableprofit": 0.5,
    "deferredtaxliabilities": 3182000,
    "deferredtaxassets": 1988000,
    "weightedaverageshares": 36987982,
    "basicearningslosspersharefromcontinuingoperations": -1.76,
    "adjustedweightedaverageshares": 36987982,
    "numberofcofoundersholdsharecapitalofrelatedparty": 4,
    "numberofemployeesholdsharecapitalofrelatedparty": 13,
    "percentageofsharecapitalheldbyrelatedparty": 0.0486,
    "amountspaidtorelatedpartytransactions": 1700000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 140000,
    "keymanagementpersonnelcompensationsharebasedpayment": 109000,
    "keymanagementpersonnelcompensationdirectorfeesofsubsidiary": 22000,
    "keymanagementpersonnelcompensation": 140000,
    "amountspayablerelatedpartytransactions": 187631000,
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the past twelve months ended",
    "ceocorporatecontractnoncompeteindemnitycompensationeligibilityperiod": "P12M",
    "ceocorporatecontractnoncompeteindemnitycompensationuponterminationdescription1": "increased, where applicable, by the amount of the annual variable compensation due for the previous year. This compensation is intended to compensate the prohibition made to the Chief Executive Officer, for a period of 12 months following the termination of his functions, for whatever reason, to work in any way whatsoever with certain companies carrying out a directly competitive activity of the Company.",
    "ceogrossnegligenceseverancepaydescription": "twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the twelve past completed months",
    "ceogrossnegligenceseverancepayeligibilityperiod": "P12M",
    "maximumcommitmentamount": 341000,
    "attendanceandotherremunerationpayable": 318613000,
    "attendanceandotherremunerationpayment": 310123000,
    "directorsremunerationwithholdingpercentage": 0.21,
    "amountoftransferpenalties": 1360000,
    "rentalpaymentobligationunderleaseagreement": 542000,
    "endowmentfund": 45000
  }
]